Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Philadelphia, US
Size (employees)
173 (est)
Adaptimmune was founded in 2008 and is headquartered in Philadelphia, US

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia and Milton
Philadelphia, US (HQ)
2010 Market St
Milton, GB
Park House Park Dr

Adaptimmune Data and Metrics

Adaptimmune Financial Metrics

Adaptimmune's revenue was reported to be $2.9 m in Q1, 2017

Revenue (Q1, 2017)

2.9 m

EBIT (Q1, 2017)

(22.2 m)

Market capitalization (21-Sep-2017)

4.7 b

Cash (31-Mar-2017)

170.6 m
Adaptimmune's current market capitalization is $4.7 b.
USDFY, 2016


9 m

R&D expense

25.5 m

General and administrative expense

9.9 m

Operating expense total

35.4 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017


2.9 m328 k2.4 m2.9 m

R&D expense

13.9 m16.2 m15.6 m18.6 m

General and administrative expense

5.9 m6.8 m5.4 m6.5 m

Operating expense total

19.7 m23 m21 m25.1 m
USDFY, 2016


158.8 m

Accounts Receivable

149.5 k


1.4 m

Current Assets

198.8 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017


163.8 m150.9 m140.4 m170.6 m

Current Assets

238.6 m218.2 m199.5 m222.9 m


13.8 m13.4 m15.1 m35.1 m

Total Assets

261.6 m239.6 m222.6 m266 m
USDFY, 2016

Net Income

(23 m)

Cash From Operating Activities

(48.2 m)

Cash From Investing Activities

17.8 m

Cash From Financing Activities

17 k
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.6 m)(22.1 m)(18.5 m)

Accounts Payable

2.4 m2.5 m3.2 m5.2 m
USDY, 2017


16.5 k

Financial Leverage

1.3 x
Show all financial metrics

Adaptimmune Operating Metrics

Adaptimmune's Patent Applications was reported to be 69 in FY, 2016
FY, 2016

Patents Issued


Patent Applications

Show all operating metrics

Adaptimmune Market Value History

Traffic Overview of Adaptimmune

Adaptimmune Online and Social Media Presence

Adaptimmune News and Updates

BRIEF-Adaptimmune says enters commercial development and supply agreement with Thermo Fisher

* Adaptimmune announces commercial development and supply agreement for Thermo Fisher scientific's Dynabeads cd3/cd28 cell therapy system

Adaptimmune Company Life and Culture

You may also be interested in